cupure logo
Trial: New Pill Nearly Doubles Survival Time for Pancreatic Cancer Patients

Trial: New Pill Nearly Doubles Survival Time for Pancreatic Cancer Patients

A clinical trial showed that the drug daraxonrasib nearly doubled survival time for patients with advanced pancreatic cancer. Experts are calling the pill a potential 'gamechanger' with fewer side effects than chemotherapy.

Comments

Read this story in other languages

Covered by the press in 2 countries

Among the outlets we follow

  • United Kingdom3
  • United States2

Similar News from External Sources

How we write our stories →

Cupure writes the day's most important stories in seven languages. The name comes from the French 'coupure de journal' — a newspaper clipping — our promise of concise, relevant news.

For advertising inquiries, content suggestions, or to flag a concern about a news item or content, you can reach us. We value your feedback. Contact form